SCHEMBL4229397

SCHEMBL4229397

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4OCC)cc3)cc2OC)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 5/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.41
CASP1 P29466 1/20 0.41
RAB9A P51151 1/20 0.41
HTR4 Q13639 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC5A7 Q9GZV3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236698 0.96 SMN1; SMN2 (0.46) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL4242394 0.92 TAS1R3 (0.43) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL4234129 0.92 MCHR1 (0.42) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL4687213 0.92 MCHR1 (0.42) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL4233219 0.92 SMN1; SMN2 (0.44) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL13699148 0.92 SMN1; SMN2 (0.44) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL4236062 0.91 MCHR1 (0.47) MCHR1SMN1; SMN2NPSR1MAPTGAA
SCHEMBL4233894 0.91 MCHR1 (0.47) MCHR1SMN1; SMN2NPSR1MAPTGAA
SCHEMBL4237451 0.91 SMN1; SMN2 (0.44) MCHR1SMN1; SMN2NPSR1MAPTLMNA
SCHEMBL4227215 0.91 SMN1; SMN2 (0.44) MCHR1SMN1; SMN2NPSR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MCHR1 47/4885SMN1; SMN2 1538/4885NPSR1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.